Sanofi has launched a new initiative in its drive to integrate digital technologies ... first task for the accelerator will be to address the needs of patients with atopic dermatitis – a key ...

Galderma has kicked off an ad campaign to show how its Nemluvio can empower people to rule over itchy eczema. Aiming to grow ...

The Digital Medicine Society (DiME) is today releasing a new set of open-access resources to advance the use of nocturnal scratch in the treatment of atopic dermatitis (AD). Night-time flare-ups ...

Dupixent, which was rejected by the FDA for chronic spontaneous urticaria in October 2023, is now approved as the first new ...

Regeneron Pharmaceuticals (REGN) and Sanofi (SNY) announced that the U.S. Food and Drug Administration has approved Dupixent for the treatment of ...

Drug is also being tested as a treatment for the skin condition atopic dermatitis, Sanofi’s next-generation experimental asthma drug failed to significantly reduce flare-ups in patients with ...

The FDA has approved Regeneron’s and Sanofi’s Dupixent ... debilitating atopic conditions driven in part by underlying type 2 inflammation, several of which have been shown to co-morbidly occur with ...